Stanislav Pantelyushin | Scientific Project Lead
University of Zurich
Stanislav Pantelyushin is a Scientific Project Lead from vom Berg group at the Institute of Laboratory Animal Science (LTK), University of Zurich, Switzerland since July 2026 having previously worked at LTK from 2017 to 2021. In the intervening years, he held positions in biotechnology and pharmaceutical companies, contributing to the development of vaccines and TCR-T cell therapies, investigating mechanisms of action of polyclonal immunoglobulin preparations at CSL Behring, and advancing in vitro diagnostic technologies at Bühlmann Laboratories. He studied Biochemistry at Imperial College London, United Kingdom. Stanislav received his PhD from the Institute of Experimental Immunology at the University of Zurich, Switzerland, in 2012, where he subsequently worked as a postdoctoral fellow before pursuing further postdoctoral research at the Department of Pathology and Immunology, University of Geneva, from 2014 to 2016. His main research interest revolves around basic and translational immunological studies aimed at developing immunotherapies for cancer in companion dogs. His work combines immunology, immunotherapy, protein engineering, and a broad range of ex vivo and in vitro techniques, with a particular focus on bridging fundamental discoveries and translational applications.
Appearances:
Festival of Biologics Day 3 @ 10:00
Canine Cancer Immunotherapy: From Immune Profiling to Checkpoint Blockade and Real World Clinical Challenges
Companion dogs with naturally occurring cancer represent a valuable translational model for investigating tumor immunology and developing immunotherapeutic approaches relevant to both veterinary and human medicine. However, robust tools for characterizing canine immune responses and evaluating therapeutic interventions remain comparatively limited.
To address these gaps we initially developed a comprehensive 14-color flow cytometry panel enabling detailed immunophenotyping and functional assessment of canine peripheral blood mononuclear cells (cPBMCs). This platform provides a standardized approach for characterization of diverse immune cell populations, their proliferation and cytokine production. Building on this, we evaluated the cross-reactivity and functionality of FDA-approved human immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 and CTLA-4 pathways in dogs. Among the 7 tested candidates, atezolizumab (anti-PD-L1) demonstrated functional blockade of canine PD-1/PD-L1, enhancing cytokine responses in vitro, particularly in lymphoma patients. Finally, we investigated the impact of prior corticosteroid treatment on immune composition and responsiveness to checkpoint blockade and IL-12 stimulation. Corticosteroid exposure altered cPBMC composition, and was associated with reduced cytokine responses to immunotherapy.
Together, these studies establish immune-monitoring tools, identify clinically available immunotherapeutic agents with activity in dogs, and highlight important treatment-related variables that may influence therapeutic outcomes.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events